Reduced Osteoclastogenesis and RANKL Expression in Marrow from Women Taking Alendronate

Overview

Journal Calcif Tissue Int

Specialty Pathology

Date 2011 Feb 18

PMID 21327765

Citations 13

Authors

Behnam Eslami

Shuanhu Zhou

Inge Van Eekeren

Meryl S LeBoff

Julie Glowacki

Affiliations

Soon will be listed here.

Abstract

Alendronate (AL) is commonly used for the prevention and treatment of osteoporotic fractures. Little is known about the effects of AL administration on osteoclast differentiation from human marrow progenitor cells. We used marrow discarded during orthopedic surgery to test the hypothesis that cultures of bone marrow-derived stem cells (BMCs) from subjects receiving AL (+AL) may differ from control subjects with respect to in vitro osteoclast differentiation and regulatory factors. The number of osteoclasts generated in BMC cultures from control subjects was 4.7-fold greater than that from +AL subjects (P = 0.015). RANKL expression in +AL BMCs was 57% of that in controls (P = 0.001), and OPG expression in +AL BMCs was greater than in controls (153%, P = 0.01). The mean RANKL/OPG ratio in BMCs was 0.65 ± 0.35 for +AL specimens and 1.28 ± 0.53 for controls (P = 0.031). In addition, we assessed the direct effect of AL on expression of RANKL and OPG in marrow stromal cells isolated from nine control women. Treatment with AL downregulated RANKL expression and upregulated OPG expression, with an average 50% decrease in RANKL/OPG ratio at 10(-7) M (P = 0.004). These results show that osteoclast differentiation is dysregulated in marrow isolated from +AL subjects. Furthermore, AL may inhibit human osteoclastogenesis by affecting the key regulatory genes in marrow cells.

Citing Articles

Evaluation of bone-protecting effects of palm carotene mixture in two- and three-dimensional osteoblast/osteoclast co-culture systems.

Yee M, Chin K, Ima-Nirwana S, Alias E, Chua K, Wong S Int J Med Sci. 2025; 22(3):585-603.

PMID: 39898246 PMC: 11783079. DOI: 10.7150/ijms.103445.

Nutraceuticals in osteoporosis prevention.

Roseti L, Borciani G, Grassi F, Desando G, Gambari L, Grigolo B Front Nutr. 2024; 11:1445955.

PMID: 39416651 PMC: 11479890. DOI: 10.3389/fnut.2024.1445955.

The Therapeutic Potential of Two Egyptian Plant Extracts for Mitigating Dexamethasone-Induced Osteoporosis in Rats: Nrf2/HO-1 and RANK/RANKL/OPG Signals.

Saleh S, Saleh O, El-Bessoumy A, Sheta E, Ghareeb D, Eweda S Antioxidants (Basel). 2024; 13(1).

PMID: 38247490 PMC: 10812806. DOI: 10.3390/antiox13010066.

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis.

Kong S, Kim J, Kim S, Jeong A, Lee S, Ye S J Bone Metab. 2022; 29(2):93-101.

PMID: 35718926 PMC: 9208900. DOI: 10.11005/jbm.2022.29.2.93.

Protosappanin a inhibits osteoclastogenesis via reducing oxidative stress in RAW264.7 cells.

Huang Q, Meng R, Yang Y, Li M, Wang F, Shen W Int J Clin Exp Pathol. 2020; 10(7):7498-7510.

PMID: 31966594 PMC: 6965276.

References

Gordon C, LeBoff M, Glowacki J . Adrenal and gonadal steroids inhibit IL-6 secretion by human marrow cells. Cytokine. 2002; 16(5):178-86. DOI: 10.1006/cyto.2001.0962. View

Fisher J, Rogers M, Halasy J, Luckman S, Hughes D, Masarachia P . Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999; 96(1):133-8. PMC: 15105. DOI: 10.1073/pnas.96.1.133. View

Atkins G, Kostakis P, Welldon K, Vincent C, Findlay D, Zannettino A . Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. J Cell Physiol. 2004; 203(3):573-82. DOI: 10.1002/jcp.20255. View

Russell R . Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007; 119 Suppl 2:S150-62. DOI: 10.1542/peds.2006-2023H. View

Liggett Jr W, Shevde N, Anklesaria P, Sohoni S, Greenberger J, Glowacki J . Effects of macrophage colony stimulating factor and granulocyte-macrophage colony stimulating factor on osteoclastic differentiation of hematopoietic progenitor cells. Stem Cells. 1993; 11(5):398-411. DOI: 10.1002/stem.5530110507. View

MacDonald B, Mundy G, Clark S, Wang E, Kuehl T, Stanley E . Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures. J Bone Miner Res. 1986; 1(2):227-33. DOI: 10.1002/jbmr.5650010210. View

Zhou S, Greenberger J, Epperly M, Goff J, Adler C, LeBoff M . Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell. 2008; 7(3):335-43. PMC: 2398731. DOI: 10.1111/j.1474-9726.2008.00377.x. View

Glowacki J . The deceiving appearances of osteoclasts. N Engl J Med. 2009; 360(1):80-2. DOI: 10.1056/NEJMe0806271. View

Van Beek E, Lowik C, Papapoulos S . Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. Bone. 1997; 20(4):335-40. DOI: 10.1016/s8756-3282(97)00006-9. View

10.

Luckman S, Hughes D, Coxon F, Graham R, Russell G, Rogers M . Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998; 13(4):581-9. DOI: 10.1359/jbmr.1998.13.4.581. View

11.

Yamada N, Tsujimura T, Ueda H, Hayashi S, Ohyama H, Okamura H . Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor. Cytokine. 2005; 31(4):288-97. DOI: 10.1016/j.cyto.2005.03.009. View

12.

Tonino R, Meunier P, Emkey R, Menkes C, Wasnich R, Bone H . Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab. 2000; 85(9):3109-15. DOI: 10.1210/jcem.85.9.6777. View

13.

Mabilleau G, Sabokbar A . Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS One. 2009; 4(1):e4173. PMC: 2613539. DOI: 10.1371/journal.pone.0004173. View

14.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J . Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343(9):604-10. DOI: 10.1056/NEJM200008313430902. View

15.

Weinstein R, Roberson P, Manolagas S . Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009; 360(1):53-62. PMC: 2866022. DOI: 10.1056/NEJMoa0802633. View

16.

Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle W, Lacey D, Riggs B . Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003; 111(8):1221-30. PMC: 152939. DOI: 10.1172/JCI17215. View

17.

Koshihara Y, Suematsu A, Feng D, Okawara R, Ishibashi H, Yamamoto S . Osteoclastogenic potential of bone marrow cells increases with age in elderly women with fracture. Mech Ageing Dev. 2002; 123(10):1321-31. DOI: 10.1016/s0047-6374(02)00071-4. View

18.

Pan B, Farrugia A, To L, Findlay D, Green J, Lynch K . The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res. 2004; 19(1):147-54. DOI: 10.1359/jbmr.2004.19.1.147. View

19.

Bone H, Hosking D, Devogelaer J, Tucci J, Emkey R, Tonino R . Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350(12):1189-99. DOI: 10.1056/NEJMoa030897. View

20.

MacDonald B, Takahashi N, McManus L, Holahan J, Mundy G, Roodman G . Formation of multinucleated cells that respond to osteotropic hormones in long term human bone marrow cultures. Endocrinology. 1987; 120(6):2326-33. DOI: 10.1210/endo-120-6-2326. View